{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:20Z","timestamp":1793239400817,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.phrs.2023.106898","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:32:00Z","timestamp":1693225920000},"page":"106898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Pillars of long-term antiretroviral therapy success"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7289-8823","authenticated-orcid":false,"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Borderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto Maurizio","family":"Celesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cingolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cossarizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"D'Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"D'Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":false,"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Marandola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Carla","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6281","authenticated-orcid":false,"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106898_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hjdsi.2015.12.002","article-title":"A design thinking framework for healthcare management and innovation","volume":"4","author":"Roberts","year":"2016","journal-title":"Health"},{"key":"10.1016\/j.phrs.2023.106898_bib2","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents., A Working Group of the Office of AIDS Research, Advisory Council (OARAC), Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, (n.d.). \u3008https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf\u3009."},{"key":"10.1016\/j.phrs.2023.106898_bib3","unstructured":"European AIDS Clinical Society (EACS), EACS GUIDELINES Version 11.1, October 2022, (n.d.). \u3008https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09\u201310.pdf\u3009."},{"key":"10.1016\/j.phrs.2023.106898_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271607","article-title":"Challenges to communicating the Undetectable equals Untransmittable (UU) HIV prevention message: healthcare provider perspectives","volume":"17","author":"Grace","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib5","unstructured":"Societ\u00e0 Italiana di Malattie Infettive e Tropicali (SIMIT) e Italian Conference on AIDS and Antiviral research (ICAR), Conferenza di consenso Italiana su UequalsU (UU),\u00a0, 2019. \u3008https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2903_allegato.pdf\u3009."},{"key":"10.1016\/j.phrs.2023.106898_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10461-021-03365-y","article-title":"Re-engagement into HIV care: a systematic review","volume":"26","author":"Blanco","year":"2022","journal-title":"AIDS Behav."},{"key":"10.1016\/j.phrs.2023.106898_bib7","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1186\/s12889-021-11613-y","article-title":"Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review","volume":"21","author":"Palacio-Vieira","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.phrs.2023.106898_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","article-title":"HIV Research Network, Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy","volume":"33","author":"Fleming","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165245","article-title":"Clonally expanded HIV-1 proviruses with 5\u2019-leader defects can give rise to nonsuppressible residual viremia","volume":"133","author":"White","year":"2023","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106898_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/cid\/cir936","article-title":"Plasma HIV-1 RNA detection below 50 copies\/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy","volume":"54","author":"Doyle","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0b013e3182567a57","article-title":"Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure","volume":"60","author":"Maggiolo","year":"2012","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/QAD.0000000000002908","article-title":"Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen","volume":"35","author":"Gianotti","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663843","article-title":"Residual viremia is linked to a specific immune activation profile in HIV-1-infected adults under efficient antiretroviral therapy","volume":"12","author":"Younas","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2023.106898_bib15","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jac\/dky106","article-title":"Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs","volume":"73","author":"Puertas","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2023.106898_bib16","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","author":"Elvstam","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00052-22","article-title":"Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells","author":"Chu","year":"2022","journal-title":"Clin. Microbiol Rev."},{"key":"10.1016\/j.phrs.2023.106898_bib18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40121-022-00676-y","article-title":"HIV DNA sequencing to detect archived antiretroviral drug resistance","volume":"11","author":"Geretti","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.phrs.2023.106898_bib19","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/JCM.00105-18","article-title":"Comparison of an in vitro diagnostic next-generation sequencing assay with sanger sequencing for HIV-1 genotypic resistance testing","volume":"56","author":"Tzou","year":"2018","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.phrs.2023.106898_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106087","article-title":"Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics","volume":"176","author":"Siamoglou","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.106898_bib21","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1093\/jac\/dkaa329","article-title":"A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV","volume":"75","author":"Guaraldi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2023.106898_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/QAI.0b013e3181e9be6b","article-title":"EuroSIDA study group, serious fatal and nonfatal non-AIDS-defining illnesses in Europe","volume":"55","author":"Mocroft","year":"2010","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"ATHENA observational cohort, Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25449","article-title":"The challenge of HIV treatment in an era of polypharmacy","volume":"23","author":"Back","year":"2020","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.phrs.2023.106898_bib25","first-page":"207","article-title":"Immunologic abnormalities in the acquired immunodeficiency syndrome","volume":"37","author":"Bowen","year":"1986","journal-title":"Prog. Allergy"},{"key":"10.1016\/j.phrs.2023.106898_bib26","doi-asserted-by":"crossref","first-page":"a3172","DOI":"10.1136\/bmj.a3172","article-title":"HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity","volume":"338","author":"Deeks","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2023.106898_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1086\/695852","article-title":"The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options","volume":"48","author":"Gazzola","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1086\/323898","article-title":"Clinical indicators of immune restoration following highly active antiretroviral therapy","volume":"34","author":"Cooney","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/QAI.0000000000002525","article-title":"Integrase inhibitors use and cytomegalovirus infection predict immune recovery in people living with HIV starting first-line therapy","volume":"86","author":"Fabbiani","year":"2021","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqac005","article-title":"SARS-CoV-2 immunity and vaccine strategies in people with HIV","volume":"3","author":"Mullender","year":"2022","journal-title":"Oxf. Open Immunol."},{"key":"10.1016\/j.phrs.2023.106898_bib31","doi-asserted-by":"crossref","first-page":"7316456","DOI":"10.1155\/2021\/7316456","article-title":"HIV-related immune activation and inflammation: current understanding and strategies","volume":"2021","author":"Lv","year":"2021","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.phrs.2023.106898_bib32","first-page":"155","article-title":"Failure of CD4+ T-cell recovery upon virally-effective cART: an enduring gap in the understanding of HIV+ immunological non-responders","volume":"45","author":"Bono","year":"2022","journal-title":"N. Microbiol"},{"key":"10.1016\/j.phrs.2023.106898_bib33","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1086\/588480","article-title":"Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART","volume":"46","author":"Isgr\u00f2","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015663","article-title":"Increased bone marrow interleukin-7 (IL-7)\/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy","volume":"5","author":"Bellistr\u00ec","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib35","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1097\/00002030-199904010-00001","article-title":"Thymus volume correlates with the progression of vertical HIV infection","volume":"13","author":"Vigano\u2019","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib36","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1097\/01.aids.0000242819.72839.db","article-title":"Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART","volume":"20","author":"Marchetti","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/cid\/cir552","article-title":"Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy","volume":"53","author":"Li","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/JLB.4A0919-235R","article-title":"Immunological recovery failure in cART-treated HIV-positive patients is associated with reduced thymic output and RTE CD4+ T cell death by pyroptosis","volume":"107","author":"Carvalho-Silva","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2023.106898_bib39","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0b013e328339cf40","article-title":"Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART","volume":"24","author":"Marchetti","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy","volume":"187","author":"Hunt","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10096-008-0582-7","article-title":"Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients","volume":"28","author":"Vajpayee","year":"2009","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1310\/hct1402-61","article-title":"Immune activation while on potent antiretroviral therapy can predict subsequent CD4+ T-Cell increases through 15 years of treatment","volume":"14","author":"Zhang","year":"2013","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.phrs.2023.106898_bib43","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1086\/651689","article-title":"Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications","volume":"50","author":"Negredo","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2018.00214","article-title":"The NLRP3 inflammasome is upregulated in HIV-Infected antiretroviral therapy-treated individuals with defective immune recovery","volume":"9","author":"Bandera","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2023.106898_bib45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/infdis\/jiaa714","article-title":"Human immunodeficiency virus-infected immunological nonresponders have colon-restricted gut mucosal immune dysfunction","volume":"225","author":"Meyer-Myklestad","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib46","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/QAD.0000000000001015","article-title":"Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy","volume":"30","author":"Tincati","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CVI.13.5.556-560.2006","article-title":"Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection","volume":"13","author":"Schacker","year":"2006","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.phrs.2023.106898_bib48","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2023.106898_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12981-016-0103-1","article-title":"Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection","volume":"13","author":"Tincati","year":"2016","journal-title":"AIDS Res Ther."},{"key":"10.1016\/j.phrs.2023.106898_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105135","article-title":"Targeting gut barrier dysfunction with phytotherapies: effective strategy against chronic diseases","volume":"161","author":"Dey","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.106898_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106687","article-title":"Gut microbiota remodeling improves natural aging-related disorders through Akkermansia muciniphila and its derived acetic acid","volume":"189","author":"Ma","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.106898_bib52","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fimmu.2016.00614","article-title":"Stimulation of PBMC and monocyte-derived macrophages via toll-like receptor activates innate immune pathways in HIV-infected patients on virally suppressive combination antiretroviral therapy","volume":"7","author":"Merlini","year":"2016","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2023.106898_bib53","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/QAD.0b013e32835cb747","article-title":"ICONA Foundation Study, Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment","volume":"27","author":"Lapadula","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1473-3099(06)70463-7","article-title":"Immunological recovery and antiretroviral therapy in HIV-1 infection","volume":"6","author":"Battegay","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib55","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciu038","volume":"58","author":"Engsig","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1479-5876-9-93","article-title":"CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution","volume":"9","author":"De Maria","year":"2011","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.phrs.2023.106898_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12916-018-1046-2","article-title":"Switching to dual\/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study","volume":"16","author":"Mussini","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.phrs.2023.106898_bib58","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.phrs.2023.106898_bib60","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2352-3018(20)30202-2","article-title":"Spanish HIV research network (CoRIS), effects of first-line antiretroviral therapy on the CD4\/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study","volume":"7","author":"Serrano-Villar","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib61","doi-asserted-by":"crossref","first-page":"20052","DOI":"10.7448\/IAS.18.1.20052","article-title":"CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients","volume":"18","author":"Lu","year":"2015","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.phrs.2023.106898_bib62","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1089\/aid.2014.0080","article-title":"Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 Ratio","volume":"30","author":"Saracino","year":"2014","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.phrs.2023.106898_bib63","doi-asserted-by":"crossref","first-page":"e00605","DOI":"10.1128\/AAC.00605-17","article-title":"A lower baseline CD4\/CD8 T-cell ratio is independently associated with immunodiscordant response to antiretroviral therapy in HIV-infected subjects","volume":"61","author":"Rosado-S\u00e1nchez","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2023.106898_bib64","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1097\/QAD.0000000000002010","article-title":"FHDH-ANRS CO4, CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era","volume":"32","author":"Roul","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.822153","article-title":"CD4+ T lymphocyte recovery in the modern antiretroviral therapy era: Toward a new threshold for defining immunological non-responders","volume":"2","author":"Taramasso","year":"2023","journal-title":"Front. Virol."},{"key":"10.1016\/j.phrs.2023.106898_bib66","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/cix466","article-title":"CD4:CD8 Ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus\u2013infected patients on antiretroviral therapy: the antiretroviral therapy cohort collaboration (ART-CC","volume":"65","author":"Trickey","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12879-021-06260-y","article-title":"Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV","volume":"21","author":"Merlini","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/QAI.0000000000002533","article-title":"Association of plasma soluble vascular cell adhesion molecule-1 and sCD14 with mortality in HIV-1-Infected West African adults with high CD4 counts","volume":"86","author":"Affi","year":"2021","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/infdis\/jiab433","article-title":"T-Cell immune dysregulation and mortality in women with human immunodeficiency virus","volume":"225","author":"Peters","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab570","article-title":"Monitoring circulating immune checkpoint proteins as predictors of non-aids morbid events in people with HIV initiating antiretroviral therapy","volume":"9","author":"Premeaux","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib71","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1097\/QAD.0000000000003048","article-title":"Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy","volume":"35","author":"Premeaux","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155100","article-title":"INSIGHT SMART\/ESPRIT\/SILCAAT study group, relevance of interleukin-6 and D-dimer for serious non-aids morbidity and death among HIV-positive adults on suppressive antiretroviral therapy","volume":"11","author":"Grund","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152588","article-title":"D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-aids events","volume":"11","author":"Freiberg","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib74","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1089\/aid.2016.0007","article-title":"Unchanged levels of soluble CD14 and IL-6 over time predict serious Non-AIDS events in HIV-1-Infected people","volume":"32","author":"Sunil","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.phrs.2023.106898_bib75","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib76","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib77","article-title":"Cytomegalovirus IgG titer and coronary artery disease in people with HIV","author":"Schnittman","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib78","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1161\/CIRCULATIONAHA.118.037487","article-title":"Elevated plasma ceramides are associated with antiretroviral therapy use and progression of carotid artery atherosclerosis in HIV infection","volume":"139","author":"Zhao","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106898_bib79","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/QAI.0000000000002001","article-title":"PD-1+ and TIGIT+ CD4 T cells are associated with coronary artery calcium progression in HIV-infected treated adults","volume":"81","author":"Bowler","year":"2019","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib80","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1097\/QAD.0000000000001149","article-title":"Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy","volume":"30","author":"Hsu","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib81","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003371","article-title":"Inflammatory markers associated with subclinical coronary artery disease: the multicenter AIDS cohort study","volume":"5","author":"Bahrami","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2023.106898_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144312","article-title":"Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher framingham and VACS risk index scores","volume":"10","author":"Mooney","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib83","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/QAD.0000000000000158","article-title":"Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection","volume":"28","author":"Longenecker","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib84","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/QAI.0000000000000339","article-title":"Monocyte activation, but not microbial translocation, is independently associated with markers of endovascular dysfunction in HIV-infected patients receiving cART","volume":"67","author":"Pedersen","year":"2014","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149601","article-title":"Higher levels of osteoprotegerin and immune activation\/immunosenescence markers are correlated with concomitant bone and endovascular damage in HIV-suppressed patients","volume":"11","author":"D\u2019Abramo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib86","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/QAD.0000000000000320","article-title":"Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study","volume":"28","author":"Hileman","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib87","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0000000000000005","article-title":"Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy","volume":"65","author":"Erlandson","year":"2014","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.809956","article-title":"Soluble insulin receptor levels in plasma, exosomes, and urine and its association with HIV-associated neurocognitive disorders","volume":"13","author":"Cantres-Rosario","year":"2022","journal-title":"Front Neurol."},{"key":"10.1016\/j.phrs.2023.106898_bib89","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/infdis\/jiy337","article-title":"RV254\/SEARCH010, SEARCH011, and RV304\/SEARCH013 Study Groups, Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV infection tracks with fewer neurological abnormalities","volume":"218","author":"D\u2019Antoni","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAI.0000000000001881","article-title":"Inflammation relates to poorer complex motor performance among adults living with HIV on suppressive antiretroviral therapy","volume":"80","author":"Montoya","year":"2019","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib91","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s13365-016-0497-5","article-title":"Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals","volume":"23","author":"P\u00e9rez-Santiago","year":"2017","journal-title":"J. Neurovirol"},{"key":"10.1016\/j.phrs.2023.106898_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157160","article-title":"Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment","volume":"11","author":"Ed\u00e9n","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib93","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0b013e318256f3bc","article-title":"Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection","volume":"60","author":"Kamat","year":"2012","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2023.106898_bib94","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/jac\/dkab168","article-title":"Redefining therapeutic success in HIV patients: an expert view","volume":"76","author":"Antela","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2023.106898_bib95","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2023.106898_bib96","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2885.2004.00600.x","article-title":"Plasma terminal half-life","volume":"27","author":"Toutain","year":"2004","journal-title":"J. Vet. Pharm. Ther."},{"key":"10.1016\/j.phrs.2023.106898_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab316","article-title":"Forgiveness of dolutegravir-based triple therapy compared with older antiretroviral regimens: a prospective multicenter cohort of adherence patterns and HIV-RNA replication","volume":"8","author":"Parienti","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib98","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"Elliot","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2023.106898_bib99","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152611795589663","article-title":"HIV treatment adherence, drug resistance, virologic failure: evolving concepts","volume":"11","author":"Nachega","year":"2011","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.phrs.2023.106898_bib100","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/QAD.0b013e32832ba8ec","article-title":"Antiretroviral medication adherence and the development of class-specific antiretroviral resistance","volume":"23","author":"Gardner","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib101","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkn020","article-title":"Forgiveness of non-adherence to HIV-1 antiretroviral therapy","volume":"61","author":"Shuter","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2023.106898_bib102","doi-asserted-by":"crossref","DOI":"10.1177\/23259582221140208","article-title":"Real World data on forgiveness to uncomplete adherence to bictegravir\/ emtricitabine\/tenofovir alafenamide","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J. Int Assoc. Provid AIDS Care"},{"key":"10.1016\/j.phrs.2023.106898_bib103","article-title":"Adherence to and forgiveness of 3TC\/DTG in a real-world cohort","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J. Int Assoc. Provid AIDS Care"},{"key":"10.1016\/j.phrs.2023.106898_bib104","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"issue":"Suppl 6","key":"10.1016\/j.phrs.2023.106898_bib105","article-title":"HIV glasgow, 23-26 october 2022, glasgow, UK \/ virtual","volume":"25","author":"Orkin","year":"2022","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.phrs.2023.106898_bib106","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2021","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.phrs.2023.106898_bib107","unstructured":"Ramgopal M., Castagna A., Cazanave C., Diaz-Brito V., Dretler R., Oka S., Osiyemi O., Sutton K., Sutherland-Phillips D., Berni A., Latham C., Zhang Z., D\u2019Amico R., Smith K., Van Wyk J., SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B\/FTC\/TAF, (n.d.). \u3008https:\/\/www.croiconference.org\/abstract\/solar-12-month-results-randomized-switch-trial-of-cabrpv-la-vs-oral-b-ftc-taf\/\u3009 (accessed May 14, 2023)."},{"key":"10.1016\/j.phrs.2023.106898_bib108","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1080\/09540121.2020.1813872","article-title":"Polypharmacy and frailty among persons with HIV","volume":"33","author":"Sung","year":"2021","journal-title":"AIDS Care"},{"key":"10.1016\/j.phrs.2023.106898_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/hiv.12628","article-title":"Italian Cohort Naive Antiretrovirals (ICONA) foundation study group, first-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate\/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate\/emtricitabine: a durability comparison","author":"Taramasso","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.phrs.2023.106898_bib110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/apc.2021.0089","article-title":"Behalf of the CISAI study group, durability of dolutegravir-based regimens: a 5-year prospective observational study","volume":"35","author":"Taramasso","year":"2021","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.phrs.2023.106898_bib111","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1089\/aid.2021.0161","article-title":"Long-term effectiveness of rilpivirine-based single-tablet regimens in a seven-year, two-center observational cohort of people living with HIV","volume":"38","author":"Taramasso","year":"2022","journal-title":"AIDS Res Hum. Retrovir."},{"key":"10.1016\/j.phrs.2023.106898_bib112","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/COH.0000000000000701","article-title":"The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy","volume":"16","author":"Nhean","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib113","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium","volume":"9","author":"Neesgaard","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib114","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","article-title":"Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies","volume":"52","author":"Dorjee","year":"2018","journal-title":"Int J. Antimicrob. Agents"},{"key":"10.1016\/j.phrs.2023.106898_bib115","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study","volume":"5","author":"Ryom","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib116","article-title":"Do integrase inhibitors cause weight gain","author":"Wood","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib117","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/hiv.13165","article-title":"Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade","volume":"23","author":"Taramasso","year":"2022","journal-title":"HIV Med."},{"key":"10.1016\/j.phrs.2023.106898_bib118","doi-asserted-by":"crossref","first-page":"17158","DOI":"10.1038\/s41598-019-53466-x","article-title":"Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice","volume":"9","author":"Fields","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2023.106898_bib119","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/QAD.0000000000001018","article-title":"Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons","volume":"30","author":"Ryom","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib120","article-title":"Long-term exposure of mice to nucleoside analogues disrupts mitochondrial DNA maintenance in cortical neurons","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106898_bib121","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/COH.0000000000000705","article-title":"An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors","volume":"16","author":"Senneker","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib122","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa485","article-title":"Comprehensive geriatric assessment in older persons with HIV","volume":"7","author":"Sangarlangkarn","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib123","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP3293","article-title":"Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study","volume":"24","author":"Halloran","year":"2019","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.phrs.2023.106898_bib124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/COH.0000000000000677","article-title":"Frailty: the current challenge for aging people with HIV","volume":"16","author":"Falutz","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12879-019-4184-z","article-title":"Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study","volume":"19","author":"Maggi","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib126","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s12879-022-07739-y","article-title":"Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity","volume":"22","author":"Maggi","year":"2022","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2023.106898_bib127","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/COH.0000000000000608","article-title":"Polypharmacy in HIV: recent insights and future directions","volume":"15","author":"Edelman","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.phrs.2023.106898_bib128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/apc.2018.0190","article-title":"Non-HIV comorbid conditions and polypharmacy among people living with HIV Age 65 or older compared with HIV-negative individuals Age 65 or Older in the United States: a retrospective claims-based analysis","volume":"33","author":"Kong","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.phrs.2023.106898_bib129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/apc.2019.0057","article-title":"Examination of polypharmacy trajectories among HIV-Positive and HIV-negative men in an ongoing longitudinal cohort from 2004 to 2016","volume":"33","author":"Ware","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.phrs.2023.106898_bib130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14787210.2021.1823217","article-title":"Enhancing care for people living with HIV: current and future monitoring approaches","volume":"19","author":"Maggiolo","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.phrs.2023.106898_bib131","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2352-3018(22)00046-7","article-title":"Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study","volume":"9","author":"Trickey","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib132","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3018(19)30345-5","article-title":"Patient-reported outcomes to enhance person-centred HIV care","volume":"7","author":"Kall","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib133","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2352-3018(19)30343-1","article-title":"Stigma reduction interventions in people living with HIV to improve health-related quality of life","volume":"7","author":"Andersson","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.phrs.2023.106898_bib134","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-Reported Outcomes Through 1 Year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)","volume":"14","author":"Chounta","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.phrs.2023.106898_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.phrs.2023.106898_bib136","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3851\/IMP2903","article-title":"Antiretroviral procurement and supply chain management","volume":"19 Suppl","author":"Ripin","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.phrs.2023.106898_bib137","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11904-021-00557-y","article-title":"Approaches to promoting linkage to and retention in HIV care in the United States: a scoping review","volume":"18","author":"Bauermeister","year":"2021","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.phrs.2023.106898_bib138","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/pgs-2017-0123","article-title":"Precision medicine for HIV: where are we","volume":"19","author":"Cusato","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2023.106898_bib139","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.12968\/bjon.2022.31.11.S23","article-title":"Resurrecting the \u201cfourth 90\u201d: towards a definition of health-related quality of life in HIV care","volume":"31","author":"Bourne","year":"2022","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.phrs.2023.106898_bib140","unstructured":"World Health Organization (WHO), Draft global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections 2022\u20132030, (n.d.). \u3008https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/who_draft_ghss_hiv_hep_stis_2022\u20132030.pdf?sfvrsn=d49c7b49_18\u3009 (Accessed 12 January 2023)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823002542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823002542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:45:18Z","timestamp":1760913918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823002542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":140,"alternative-id":["S1043661823002542"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106898","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pillars of long-term antiretroviral therapy success","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106898"}}